cd40 ligand
CD154, also called CD40 ligand or CD40L, is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily of molecules. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In total CD40L has three binding partners: CD40, α5β1 integrin and integrin αIIbβ3. CD154 acts as a costimulatory molecule and is particularly important on a subset of T cells called T follicular helper cells. On TFH cells, CD154 promotes B cell maturation and function by engaging CD40 on the B cell surface and therefore facilitating cell-cell communication. A defect in this gene results in an inability to undergo immunoglobulin class switching and is associated with hyper IgM syndrome. Absence of CD154 also stops the formation of germinal centers and therefore prohibits antibody affinity maturation, an important process in the adaptive immune system. — Wikipedia
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Dec 23, 1996 (NCT00001564)
Timeline
Indications
Mechanism of action
Tumor necrosis factor receptor superfamily member 5 agonist
CD40 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCD154 ↗
- ChEMBLCHEMBL4297718 ↗
Also known as
- cd40 ligand
- recombinant cd40-ligand
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00224354 | Phase 1 | Sep 1, 2005 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00053391 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2002 | University of Erlangen-Nuremberg |
| NCT00056134 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2002 | University of Erlangen-Nuremberg |
| NCT00020540 | Phase 1 | Mar 1, 2001 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00006113 | Phase 2 | Jun 1, 1999 | National Cancer Institute (NCI), University of Southern California |
| NCT00001564 | Phase 2 | Dec 23, 1996 | National Cancer Institute (NCI) |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 2 | 2 | 1996 |
| University of Erlangen-Nuremberg | Academic/Hospital | 2 | 2 | 1 | 2002 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2005 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2001 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 1999 |